MeSH tree: D03.383.725.050
Researchers at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine have developed a topical gel formulation with 4-aminopyridine (4-AP), to treat burn wounds, achieving near-complete ...
22 hours ago
0
17
A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted a head-to-head ...
May 19, 2026
0
3
A team led by Northwestern University and Shirley Ryan AbilityLab scientists have developed a new technology that can eavesdrop on the hidden electrical dialogues unfolding inside miniature, lab-grown human brain-like tissues. ...
Feb 18, 2026
0
27
Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ...
Sep 7, 2025
0
21
Researchers at the University of Arizona College of Medicine—Tucson found evidence that a drug that improves the ability to walk in people with multiple sclerosis can also make bone fractures heal faster.
Aug 29, 2025
0
33
Major depressive disorder (MDD) is a serious mental health condition that impacts individuals of all ages, including children and adolescents. Early detection and diagnosis, especially at an earlier age, is crucial for effective ...
Mar 11, 2025
0
16
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions like schizophrenia or depression.
Nov 18, 2024
0
51
A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).
A Pfizer lung cancer drug has been shown to greatly reduce tumor progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday.
May 31, 2024
0
33
A new editorial paper titled "Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer" has been published in Oncotarget.
Sep 11, 2023
0
35
